← Back to Search

Oxygen Therapy

Nocturnal Oxygen Needs and Central Sleep Apnea in Patients With Chronic Heart Failure. (HO2F Trial)

Phase 4
Waitlist Available
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three months ( titration completed 3 times during the study period)
Awards & highlights
Drug Has Already Been Approved
No Placebo-Only Group
Pivotal Trial

Summary

This trial is testing different levels of oxygen flow during sleep in order to minimize oxygen desaturation while also minimizing periods of hyperoxia.

Eligible Conditions
  • Chronic Heart Failure
  • Central Sleep Apnea

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three months ( titration completed 3 times during the study period)
This trial's timeline: 3 weeks for screening, Varies for treatment, and three months ( titration completed 3 times during the study period) for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Accuracy of automated oxygen titration
Changes in optimal levels of O2 flow ( EO2F) which prevent nocturnal O2 desaturation

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Oxygen therapyExperimental Treatment1 Intervention
Fixed nightime oxygen therapy throughout the protocol duration

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
434 Previous Clinical Trials
178,527 Total Patients Enrolled
OxynovUNKNOWN
Philips RespironicsIndustry Sponsor
67 Previous Clinical Trials
9,674 Total Patients Enrolled
~2 spots leftby Jan 2026